💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Thonzonium Bromide

CHEMBL1200883 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
591.7 g/mol
LogP
—
Phase
4

Thonzonium bromide is the bromide salt form of thonzonium, a quaternary ammonium surfactant used as a penetration enhancer in otic combination drug products. See thonzonium for complete pharmacological details. This salt formulation is used in combination otic drops for otitis externa.

Molecular Weight

591.7000 g/mol

TPSA

38.30 Ų

Mechanism of Action

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1.[Br-]

                

                

                
                

                    
InChI

                    
InChI=1S/C32H55N4O.BrH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27-36(2,3)28-26-35(32-33-24-19-25-34-32)29-30-20-22-31(37-4)23-21-30;/h19-25H,5-18,26-29H2,1-4H3;1H/q+1;/p-1

                

                

                

                    
                    

                        
Molecular Formula

                        
C32H55BrN4O

                    

                    
                    

                        
HBD / HBA

                        
- / 5

                    

                    
                    

                        
Rotatable Bonds

                        
22

                    

                    
                    
                    

                        
Heavy Atoms

                        
38

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
Thonzonium bromide is the bromide salt form of thonzonium, a quaternary ammonium surfactant used as a penetration enhancer in otic combination drug products. See thonzonium for complete pharmacological details. This salt formulation is used in combination otic drops for otitis externa.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Thonzonium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200883.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11102.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.